MDT
96.14
-0.57%↓
A
136.19
-1%↓
VEEV
223.11
-0.69%↓
HQY
91.51
-0.5%↓
PHR.US
16.9
-0.59%↓
MDT
96.14
-0.57%↓
A
136.19
-1%↓
VEEV
223.11
-0.69%↓
HQY
91.51
-0.5%↓
PHR.US
16.9
-0.59%↓
MDT
96.14
-0.57%↓
A
136.19
-1%↓
VEEV
223.11
-0.69%↓
HQY
91.51
-0.5%↓
PHR.US
16.9
-0.59%↓
MDT
96.14
-0.57%↓
A
136.19
-1%↓
VEEV
223.11
-0.69%↓
HQY
91.51
-0.5%↓
PHR.US
16.9
-0.59%↓
MDT
96.14
-0.57%↓
A
136.19
-1%↓
VEEV
223.11
-0.69%↓
HQY
91.51
-0.5%↓
PHR.US
16.9
-0.59%↓
24h
Current
Min
29.93
Max
30.81
Income | 3.8M -39M |
|---|---|
Sales | 7K 15K |
EPS | -2.13 |
Profit margin | -258,973.333 |
Employees | 300 |
EBITDA | 6.3M -36M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -7.41% downside |
Market Cap | 426M 766M |
|---|---|
Previous open | 32.22 |
Previous close | 30.51 |
By Trading Central
Confidence
Strong Bearish Evidence
0.4217 / 0.4691 Support & Resistance
Past performance is not a reliable indicator of future results.
31 Dec 2025, 22:20 UTC
Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug
DJ
Read
31 Dec 2025, 17:31 UTC
OwlTing Climbs on Launch of $10 Million Stock-Buyback Program
DJ
Read
31 Dec 2025, 16:30 UTC
Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders
DJ
Read
31 Dec 2025, 15:19 UTC
Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing
DJ
Read
31 Dec 2025, 15:17 UTC
Nike Shares Rise After CEO Hill Buys $1 Million of Shares
DJ
Read
31 Dec 2025, 14:37 UTC
Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application
DJ
Read
1 Jan 2026, 23:35 UTC
Gold Rises Amid Geopolitical Risks -- Market Talk
DJ
Read
1 Jan 2026, 21:29 UTC
BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13
DJ
Read
1 Jan 2026, 21:29 UTC
BlueScope Sold Stake in JV to Tata Steel
DJ
Read
1 Jan 2026, 21:28 UTC
BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31
DJ
Read
1 Jan 2026, 17:20 UTC
Basic Materials Roundup: Market Talk
DJ
Read
1 Jan 2026, 09:20 UTC
Basic Materials Roundup: Market Talk
DJ
Read
31 Dec 2025, 21:50 UTC
Basic Materials Roundup: Market Talk
DJ
Read
31 Dec 2025, 21:13 UTC
10 People to Watch in Wealth Management in 2026 -- Barrons.com
DJ
Read
31 Dec 2025, 20:40 UTC
Dollar Posting Its Worst Year Since 2017 -- Market Talk
DJ
Read
31 Dec 2025, 20:22 UTC
Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk
DJ
Read
31 Dec 2025, 19:50 UTC
U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk
DJ
Read
31 Dec 2025, 19:31 UTC
Precious Metals Cap Off Record Runs -- Market Talk
DJ
Read
31 Dec 2025, 18:50 UTC
Global Equities Roundup: Market Talk
DJ
Read
31 Dec 2025, 18:50 UTC
Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk
DJ
Read
31 Dec 2025, 17:17 UTC
U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk
DJ
Read
31 Dec 2025, 17:16 UTC
OwlTing Climbs on Launch of $10M Stock-Buyback Program
DJ
Read
31 Dec 2025, 17:15 UTC
Global Commodities Roundup: Market Talk
DJ
Read
31 Dec 2025, 17:00 UTC
Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ
DJ
Read
31 Dec 2025, 15:57 UTC
Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com
DJ
Read
31 Dec 2025, 15:54 UTC
Layoff Data Supports Dollar at End of Losing Year -- Market Talk
DJ
Read
31 Dec 2025, 15:02 UTC
Nike Shares Rise After CEO Hill Buys $1M of Shares
DJ
Read
31 Dec 2025, 14:40 UTC
Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com
DJ
Read
31 Dec 2025, 14:20 UTC
Crude Futures On Track to End the Year With Losses -- Market Talk
DJ
Read
31 Dec 2025, 13:46 UTC
U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 28.5 USD -7.41%
High 45 USD
Low 12 USD
Based on 2 Wall Street analysts offering 12 month price targets forLyell Immunopharma Inc - Dist in the last 3 months.
By TipRanks
Neutral
2 ratings
1
Buy
0
Hold
1
Sell
Based on 2 analysts giving stock ratings to Lyell Immunopharma Inc - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Weak Bearish Evidence
There is one bearish event.
Long Term
No Evidence
There are no events.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$